These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 12694182

  • 1. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
    Chua AC, Ingram HA, Raymond KN, Baker E.
    Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
    [Abstract] [Full Text] [Related]

  • 2. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S, Thephinlap C, Phisalaphong C, Porter JB, Fucharoen S.
    Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
    [Abstract] [Full Text] [Related]

  • 3. Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells.
    Parkes JG, Randell EW, Olivieri NF, Templeton DM.
    Biochim Biophys Acta; 1995 Apr 13; 1243(3):373-80. PubMed ID: 7727512
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis.
    Chua AC, Olynyk JK, Leedman PJ, Trinder D.
    Blood; 2004 Sep 01; 104(5):1519-25. PubMed ID: 15155457
    [Abstract] [Full Text] [Related]

  • 7. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
    Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, Xiao G, van der Helm D.
    J Med Chem; 1993 Aug 20; 36(17):2448-58. PubMed ID: 8355246
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.
    Gaboriau F, Chantrel-Groussard K, Rakba N, Loyer P, Pasdeloup N, Hider RC, Brissot P, Lescoat G.
    Biochem Pharmacol; 2004 Apr 15; 67(8):1479-87. PubMed ID: 15041465
    [Abstract] [Full Text] [Related]

  • 11. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats.
    Brissot P, Bolder U, Schteingart CD, Arnaud J, Hofmann AF.
    Hepatology; 1997 Jun 15; 25(6):1457-61. PubMed ID: 9185768
    [Abstract] [Full Text] [Related]

  • 12. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
    Kicic A, Chua AC, Baker E.
    Anticancer Drug Des; 2001 Jun 15; 16(4-5):195-207. PubMed ID: 12049478
    [Abstract] [Full Text] [Related]

  • 13. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
    Brock JH, Licéaga J, Arthur HM, Kontoghiorghes GJ.
    Am J Hematol; 1990 May 15; 34(1):21-5. PubMed ID: 2327400
    [Abstract] [Full Text] [Related]

  • 14. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
    J Clin Pathol; 1987 Apr 15; 40(4):404-8. PubMed ID: 3584483
    [Abstract] [Full Text] [Related]

  • 15. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
    Wongjaikam S, Kumfu S, Khamseekaew J, Sripetchwandee J, Srichairatanakool S, Fucharoen S, Chattipakorn SC, Chattipakorn N.
    PLoS One; 2016 Apr 15; 11(7):e0159414. PubMed ID: 27428732
    [Abstract] [Full Text] [Related]

  • 16. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
    Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P.
    Free Radic Biol Med; 1992 Nov 15; 13(5):499-508. PubMed ID: 1334028
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ.
    Toxicol Lett; 1995 Oct 15; 80(1-3):1-18. PubMed ID: 7482575
    [Abstract] [Full Text] [Related]

  • 18. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
    Vlachodimitropoulou Koumoutsea E, Garbowski M, Porter J.
    Br J Haematol; 2015 Sep 15; 170(6):874-83. PubMed ID: 26033030
    [Abstract] [Full Text] [Related]

  • 19. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
    Maclean KH, Cleveland JL, Porter JB.
    Blood; 2001 Dec 15; 98(13):3831-9. PubMed ID: 11739193
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
    Chenoufi N, Hubert N, Loréal O, Morel I, Pasdeloup N, Cillard J, Brissot P, Lescoat G.
    J Hepatol; 1995 Aug 15; 23(2):166-73. PubMed ID: 7499788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.